Lonza Prices EUR 1 Billion Straight Bond with a 3.875% Coupon
Lonza Finance International NV, a wholly owned company of Lonza Group Ltd, Basel (“Lonza”), announced today the pricing…
Lonza Finance International NV, a wholly owned company of Lonza Group Ltd, Basel (“Lonza”), announced today the pricing…
Annual General Meeting will take place on 8 May 2024 at the Congress Center in Basel, Switzerland Albert M. Baehny will…
Lonza has signed an agreement to acquire the Genentech manufacturing facility in Vacaville (US) from Roche for USD 1.2 b…
Robust sales of CHF 6.7 billion, delivering 10.9%1 CER sales growth CORE EBITDA of CHF 2 billion, resulting in a margin…
At its Capital Markets Day, Lonza outlined its Mid-Term Guidance for 2024 to 2028, including: 11–13% sales growth, 3…
. New agreement to establish global commercial manufacturing capacity for Vaxcyte's PCV candidates, VAX-24 and VAX-31,…
The new cGMP filling line at Lonza’s Stein (CH) site will enable handling and filling of bioconjugates for commercia…
Extended long-term collaboration to provide significant additional bioconjugation capacity for commercialization of…
Capital Markets Day 2023 will be hosted by members of the Lonza Executive Committee The presentation will provide an ove…
In H1 2023, Lonza delivered CHF 3.1 billion sales and 5.6% CER1 sales growth, corresponding to around 10% CER underlying…